NorthWest Biotherapeutics Inc (NWBO)

[alexander77]

Someone on Yahoo posted this:
“We were told that 28% of the phase III patients survived and made it to 36 months which sounds good but 40% of the phase III patients have methylated genes, and such patients have median Overall Survival of 66.8 months with just current standard of care. So there is nothing unexpected about 28% surviving 36 months…
66.8 months for patients with methylated gene...
"Kaplan-Meier survival analysis showed that MGMT(methylated)/IDH1(+ve) was associated with a significantly longer OS 66.8 months (95 % CI: 0.0-167.8) and PFS 16.9 months (95 % CI: 11.1-22.7) when compared with MGMT(methylated)/IDH1(-ve) OS 15.5 months (95 % CI: 11.6-19.4) and PFS 9.4 months (95 % CI: 8-10.8) (log-rank, P?=?0.000) and MGMT(unmethylated)/IDH1(-ve) OS 11.1 months (95 % CI: 8.5-13.7) and PFS 6.3 months (95 % CI: 4.4-8.3) (log-rank, p?=?0.000)."

What do you guys think of that?